{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:01:20Z","timestamp":1791050480337,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023-MS-265"],"award-info":[{"award-number":["2023-MS-265"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bbadis.2023.166930","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T01:55:49Z","timestamp":1698803749000},"page":"166930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"1870","author":[{"given":"Shuai","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangning","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2023.166930_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbadis.2023.166930_bb0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.freeradbiomed.2015.12.014","article-title":"Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development","volume":"91","author":"Ramadori","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbadis.2023.166930_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.redox.2018.01.009","article-title":"Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches","volume":"15","author":"Borrelli","year":"2018","journal-title":"Redox Biol."},{"issue":"5","key":"10.1016\/j.bbadis.2023.166930_bb0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","article-title":"The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome","volume":"7","author":"Lim","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.31220","article-title":"N-methyladenosine reader protein YT521-B homology domain-containing 2 suppresses liver steatosis by regulation of mRNA stability of lipogenic genes","volume":"73","author":"Zhou","year":"2021","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"10.1016\/j.bbadis.2023.166930_bb0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96151","article-title":"LRH-1 regulates hepatic lipid homeostasis and maintains arachidonoyl phospholipid pools critical for phospholipid diversity","volume":"3","author":"Miranda","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.bbadis.2023.166930_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"issue":"42","key":"10.1016\/j.bbadis.2023.166930_bb0045","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.3748\/wjg.v23.i42.7495","article-title":"Current and emerging pharmacological therapy for non-alcoholic fatty liver disease","volume":"23","author":"Eshraghian","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.bbadis.2023.166930_bb0050","doi-asserted-by":"crossref","first-page":"G829","DOI":"10.1152\/ajpgi.00155.2013","article-title":"Mechanisms of STAT3 activation in the liver of FXR knockout mice, American journal of physiology","volume":"305","author":"Li","year":"2013","journal-title":"Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.bbadis.2023.166930_bb0055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s12276-023-00932-2","article-title":"The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0060","doi-asserted-by":"crossref","first-page":"G48","DOI":"10.1152\/ajpgi.00234.2013","article-title":"FXR silencing in human colon cancer by DNA methylation and KRAS signaling, American journal of physiology","volume":"306","author":"Bailey","year":"2014","journal-title":"Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.taap.2018.04.015","article-title":"Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro","volume":"348","author":"Gao","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbadis.2023.166930_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114886","article-title":"Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR)","volume":"245","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbadis.2023.166930_bb0080","doi-asserted-by":"crossref","first-page":"3589525","DOI":"10.1155\/2022\/3589525","article-title":"Farnesoid X receptor deficiency induces hepatic lipid and glucose metabolism disorder via regulation of pyruvate dehydrogenase kinase 4","volume":"2022","author":"Deng","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"6","key":"10.1016\/j.bbadis.2023.166930_bb0085","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/hep.32577","article-title":"Hepatocellular cystathionine \u03b3 lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor","volume":"76","author":"Xu","year":"2022","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.bbadis.2023.166930_bb0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4049\/jimmunol.2100734","article-title":"Regulation of the NLRP3 inflammasome by posttranslational modifications","volume":"208","author":"Zangiabadi","year":"2022","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"7237","key":"10.1016\/j.bbadis.2023.166930_bb0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature07710","article-title":"AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA","volume":"458","author":"Fernandes-Alnemri","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2023.166930_bb0100","article-title":"Pseudorabies virus infection activates the TLR-NF-\u03baB axis and AIM2 inflammasome to enhance inflammatory responses in mice","author":"Zhou","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0105","article-title":"Roxadustat (FG-4592) protects against ischemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation","author":"Yang","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bbadis.2023.166930_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2022.157500","article-title":"Cadmium exposure induces pyroptosis in testicular tissue by increasing oxidative stress and activating the AIM2 inflammasome pathway","volume":"847","author":"Zhou","year":"2022","journal-title":"Sci. Total Environ."},{"issue":"18","key":"10.1016\/j.bbadis.2023.166930_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186535","article-title":"The emerging relevance of AIM2 in liver disease","volume":"21","author":"Lozano-Ruiz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbadis.2023.166930_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166793","article-title":"Apolipoprotein E \u03b54 triggers neurotoxicity via cholesterol accumulation, acetylcholine dyshomeostasis, and PKC\u03b5 mislocalization in cholinergic neuronal cells","volume":"1869","author":"Piccarducci","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"7","key":"10.1016\/j.bbadis.2023.166930_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166761","article-title":"Heme induced progesterone-resistant profiling and promotion of endometriosis in vitro and in vivo","volume":"1869","author":"Ma","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"7","key":"10.1016\/j.bbadis.2023.166930_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166770","article-title":"Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice","volume":"1869","author":"Iwai","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40168-022-01264-5","article-title":"Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity","volume":"10","author":"M\u00fcnzker","year":"2022","journal-title":"Microbiome"},{"key":"10.1016\/j.bbadis.2023.166930_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111616","article-title":"Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism","volume":"549","author":"Zhou","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cbi.2017.10.010","article-title":"Baicalin protects AML-12 cells from lipotoxicity via the suppression of ER stress and TXNIP\/NLRP3 inflammasome activation","volume":"278","author":"Zhang","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.bbadis.2023.166930_bb0150","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.7150\/ijbs.42376","article-title":"The GR-gp78 pathway is involved in hepatic lipid accumulation induced by overexpression of 11\u03b2-HSD1","volume":"18","author":"Hu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.bbadis.2023.166930_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcmgh.2021.01.019","article-title":"SMN depleted mice offer a robust and rapid onset model of nonalcoholic fatty liver disease","volume":"12","author":"Deguise","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174959","article-title":"The lactate receptor GPR81 mediates hepatic lipid metabolism and the therapeutic effect of metformin on experimental NAFLDs","volume":"924","author":"Wu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0170","article-title":"RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling","author":"Zhang","year":"2022","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.bbadis.2023.166930_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109558","article-title":"Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS\/TXNIP\/NLRP3 pathway","volume":"114","author":"Jiang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbadis.2023.166930_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2018.12.034","article-title":"Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: a mechanism involving Toll-like receptor 4 and oxidative stress","volume":"134","author":"Chenxu","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"13","key":"10.1016\/j.bbadis.2023.166930_bb0185","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1042\/CS20220380","article-title":"Early biochemical observations point to nutritional strategies to manage non-alcoholic fatty liver disease","volume":"136","author":"Calder","year":"2022","journal-title":"Clin. Sci. (London, England: 1979)"},{"issue":"4","key":"10.1016\/j.bbadis.2023.166930_bb0190","article-title":"Lingonberry improves non-alcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress and inflammatory response","volume":"10","author":"Madduma Hewage","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.bbadis.2023.166930_bb0195","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31568","article-title":"Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice","volume":"73","author":"Lin","year":"2021","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.bbadis.2023.166930_bb0200","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1089\/ars.2021.0157","article-title":"Inhibition of fatty acid translocase (FAT\/CD36) palmitoylation enhances hepatic fatty acid \u03b2-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1","volume":"36","author":"Zeng","year":"2022","journal-title":"Antioxid. Redox Signal."},{"issue":"12","key":"10.1016\/j.bbadis.2023.166930_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124534","article-title":"SGL 121 attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism through AMPK signaling pathway","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bbadis.2023.166930_bb0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2023.166930_bb0215","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.csbj.2023.05.026","article-title":"Structural basis of the farnesoid X receptor\/retinoid X receptor heterodimer on inverted repeat DNA","volume":"21","author":"Jiang","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"9","key":"10.1016\/j.bbadis.2023.166930_bb0220","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jnutbio.2015.03.011","article-title":"Activation of hepatic CREBH and Insig signaling in the anti-hypertriglyceridemic mechanism of R-\u03b1-lipoic acid","volume":"26","author":"Tong","year":"2015","journal-title":"J. Nutr. Biochem."},{"issue":"4","key":"10.1016\/j.bbadis.2023.166930_bb0225","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0036-1597248","article-title":"Regulation of hepatocellular fatty acid uptake in mouse models of fatty liver disease with and without functional leptin signaling: roles of NfKB and SREBP-1C and the effects of spexin","volume":"36","author":"Ge","year":"2016","journal-title":"Semin. Liver Dis."},{"issue":"15","key":"10.1016\/j.bbadis.2023.166930_bb0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154113","article-title":"SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface","volume":"7","author":"Zhao","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bbadis.2023.166930_bb0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-022-03540-2","article-title":"Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway","volume":"20","author":"Li","year":"2022","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.bbadis.2023.166930_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/nu14122530","article-title":"Ferulic acid prevents nonalcoholic fatty liver disease by promoting fatty acid oxidation and energy expenditure in C57BL\/6 mice fed a high-fat diet","volume":"14","author":"Luo","year":"2022","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.bbadis.2023.166930_bb0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1478-3231.2006.01265.x","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver","volume":"26","author":"Harano","year":"2006","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.bbadis.2023.166930_bb0250","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1039\/C9FO00318E","article-title":"Hepatoprotection of auraptene from the peels of citrus fruits against 17\u03b1-ethinylestradiol-induced cholestasis in mice by activating farnesoid X receptor","volume":"10","author":"Wang","year":"2019","journal-title":"Food Funct."},{"issue":"7","key":"10.1016\/j.bbadis.2023.166930_bb0255","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.4049\/jimmunol.1202817","article-title":"Critical role of ASC inflammasomes and bacterial type IV secretion system in caspase-1 activation and host innate resistance to Brucella abortus infection","volume":"190","author":"Gomes","year":"2013","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"13","key":"10.1016\/j.bbadis.2023.166930_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137447","article-title":"The P2X7R-NLRP3 and AIM2 inflammasome platforms mark the complexity\/severity of viral or metabolic liver damage","volume":"23","author":"Rossi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbadis.2023.166930_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1452","article-title":"Released dsDNA-triggered inflammasomes serve as intestinal radioprotective targets","volume":"12","author":"Chen","year":"2023","journal-title":"Clin. Transl. Immunol."},{"issue":"11","key":"10.1016\/j.bbadis.2023.166930_bb0270","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1136\/gutjnl-2020-321774","article-title":"Hepatic Kr\u00fcppel-like factor 16 (KLF16) targets PPAR\u03b1 to improve steatohepatitis and insulin resistance","volume":"70","author":"Sun","year":"2021","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.bbadis.2023.166930_bb0275","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1039\/D2FO00199C","article-title":"Corn peptides improved obesity-induced non-alcoholic fatty liver disease through relieving lipid metabolism, insulin resistance and oxidative stress","volume":"13","author":"Wei","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.bbadis.2023.166930_bb0280","doi-asserted-by":"crossref","first-page":"114050","DOI":"10.1016\/j.biopha.2022.114050","article-title":"Elafibranor modulates ileal macrophage polarization to restore intestinal integrity in NASH: Potential crosstalk between ileal IL-10\/STAT3 and hepatic TLR4\/NF-\u03baB axes","volume":"157","author":"Hakeem","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2023.166930_bb0285","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2019.02.019","article-title":"Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice","volume":"41","author":"Rom","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443923002971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443923002971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:02:15Z","timestamp":1738436535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443923002971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0925443923002971"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2023.166930","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2023.166930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166930"}}